<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513288</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_9778_ICITRU</org_study_id>
    <secondary_id>2020-A01804-35</secondary_id>
    <nct_id>NCT04513288</nct_id>
  </id_info>
  <brief_title>ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock</brief_title>
  <acronym>ICITRU</acronym>
  <official_title>ICITRU : Randomized Trial of Immunonutrition With L-citrulline in Patients Hospitalized in Intensive Care for Sepsis or Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunonutrition in intensive care has not yet demonstrated a beneficial effect on organ&#xD;
      failure, the acquisition of nosocomial infections, or mortality. It did not correct for&#xD;
      acquired immunosuppression in intensive care patients. Despite numerous methodological&#xD;
      problems (use of several pharmaconutrients, very heterogeneous set of patients) and the&#xD;
      absence of clinical data, deleterious effects have been attributed to immunonutrition in&#xD;
      intensive care, in particular in septic patients and patients in intensive care . Arginine&#xD;
      (ARG) is a semi-essential amino acid involved in many immunological mechanisms. It is&#xD;
      synthesized in sufficient quantity under normal conditions but quickly becomes insufficient&#xD;
      under catabolic conditions such as in severe sepsis. Arginine is not only the precursor of&#xD;
      nitrogen monoxide (NO) but also an essential substrate for numerous enzymatic reactions which&#xD;
      participate in the maintenance of immune homeostasis, in particular T lymphocyte function.&#xD;
      Depletion of the cellular medium in arginine will induce an abnormality in the metabolism of&#xD;
      immune cells responsible for a dysfunction of these cells (lymphopenia linked to early&#xD;
      apoptosis) and thus expose patients to organ failure and nosocomial infections.&#xD;
&#xD;
      It has been found that hypoargininemia in intensive care patients is associated with the&#xD;
      persistence of organ dysfunction (SOFA score), the occurrence of nosocomial infections and&#xD;
      mortality. Also, it has been demonstrated that in these patients, enteral administration of&#xD;
      ARG was not deleterious and increased ornithine synthesis, suggesting a preferential use of&#xD;
      ARG via the arginases route, without significant increase in argininaemia or effect on immune&#xD;
      functions. L-citrulline (CIT), an endogenous precursor of ARG, constitutes an interesting&#xD;
      alternative for increasing the availability of ARG. Sponsor recent data demonstrate that the&#xD;
      administration of CIT in intensive care is not deleterious and that it very significantly&#xD;
      reduces mortality in an animal model of sepsis, corrects hypoargininemia, with convincing&#xD;
      data on immunological parameters such as lymphopenia, which is associated with mortality,&#xD;
      organ dysfunction and the occurrence of nosocomial infections. The availability of ARG&#xD;
      directly impacts the mitochondrial metabolism of T lymphocytes and their function. Our&#xD;
      hypothesis is therefore that CIT supplementation is more effective than administration of ARG&#xD;
      in correcting hypoargininemia, reducing lymphocyte dysfunction, correcting immunosuppression&#xD;
      and organ dysfunction in septic patients admitted to intensive care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Strategy :&#xD;
&#xD;
      Enteral administration of citrulline for 5 days versus iso-nitrogenous placebo. Amino acid&#xD;
      assay and immunological parameters (monocytic expression of HLA-DR, MDSCs, cytokines /&#xD;
      chemokines, lymphocyte number and phenotype, apoptosis and lymphocyte proliferation and&#xD;
      mitochondrial function and T lymphocyte repertoire) will only be carried out on patients&#xD;
      included in Rennes (60 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, multicenter, placebo-controlled, randomized, double-blind study on two parallel groups.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Prospective, multicenter, placebo-controlled, randomized, double-blind study on two parallel groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Baseline and day 7 or last known SOFA score if the patient died or left intensive care before day 7.</time_frame>
    <description>SOFA score for organ failure (5 parameters ranged from 0 to 4 each)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nosocomial infections</measure>
    <time_frame>From Inclusion up to Day 28 maximum</time_frame>
    <description>Incidence of nosocomial infections during the stay in intensive care (maximum Day 28). The diagnosis of nosocomial infections will be made by following the definitions of nosocomial infections of the CDC (Centers for Disease Control). An independent committee of experts will validate or not the infections.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure to each antibiotic</measure>
    <time_frame>Up to Day 28 maximum</time_frame>
    <description>Number of days of exposure to each antibiotic per 1000 days of hospitalization (maximum Day 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality in intensive care</measure>
    <time_frame>Up to Day 28 maximum</time_frame>
    <description>Mortality in intensive care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>Up to Day 28 maximum</time_frame>
    <description>Hospital mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and phenotypes of lymphocytes</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>Number and phenotypes of lymphocytes on Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HLA-DR monocytic expression</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>HLA-DR monocytic expression (flow cytometry) on Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Myeloid-derived suppressor cells</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>Number of Myeloid-derived suppressor cells (flow cytometry) at on Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma cytokines / chemokines</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>Plasma cytokines / chemokines (IL-6, IL-8, IL-10, IL-7, CXCL10, G-CSF, TNF-alpha, IFN-Î²) on on Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T repertoire</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>Diversity of the T repertoire at Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T lymphocyte exhaustion</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>T lymphocyte exhaustion: measurement of lymphocytic apoptosis and lymphocyte proliferation on Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial activity</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>Measurement of mitochondrial activity (measurement of the number of mitochondria and their membrane potential, measurement of Beclin1 expression) on Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma amino acids</measure>
    <time_frame>Day 1, 3 and 7</time_frame>
    <description>Plasma amino acids (arginine and its metabolites (ornithine, glutamate, glutamine, citrulline, proline) and tryptophan / kynurenine) on Day 1, Day 3 and Day 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score</measure>
    <time_frame>Day 3 and Day 5</time_frame>
    <description>SOFA score for organ failures on Day 3 and Day 5 (5 parameters ranged from 0 to 4 each)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization in intensive care</measure>
    <time_frame>Up to Day 28 maximum</time_frame>
    <description>Duration of hospitalization in intensive care (days), up to Day 28 maximum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization at the hospital</measure>
    <time_frame>Up to Day 28 maximum</time_frame>
    <description>Hospital stay at the hospital (days), up to Day 28 maximum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Up to Day 28 maximum</time_frame>
    <description>Duration of mechanical ventilation (days), up to Day 28 maximum.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enteral administration of citrulline for 5 days. L-citrulline (ProtÃ©ocitÂ®). This commercial form consists only of L-citrulline. Each patient will receive 10 grams per day in 2 doses (1 stick/ 12H = 5 grams / 12H). These sticks contain a powder to be resuspended in 50 mL of water for injection (ppi) for 1 stick. They will be delivered in a 50 mL syringe allowing administration of the product through the nasogastric tube. The solution will be prepared just before administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Enteral administration of iso-nitrogenous placebo for 5 days. The placebo used will consist of a mixture of 4 non-essential amino acids. 5 g of L-citrulline provides 1.2 g of nitrogen. For the mixture to be iso-nitrogenous, each of the 4 amino acids will need to provide 0.3 g of nitrogen. The mixture will therefore consist of 21.6% alanine, 32.3% aspartate, 18.2% glycine and 27.9% proline for a total of 8.83 g of amino acids per sachet. 2 administrations (2 sticks) daily for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental treatment L-citrulline (ProtÃ©ocitÂ®)</intervention_name>
    <description>Enteral administration of citrulline for 5 days.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo treatment</intervention_name>
    <description>Enteral administration of iso-nitrogenous placebo for 5 days.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Septic patients in accordance with the definition of sepsis and septic shock published&#xD;
             in 2016 (JAMA) and whose use is recommended by the European Society of Intensive Care&#xD;
             Medicine;&#xD;
&#xD;
          -  Initial aggression dated less than 4 days before admission to intensive care&#xD;
             (selection of &quot;community&quot; patients). The onset of aggression will be defined by the&#xD;
             onset of clinical signs of infection;&#xD;
&#xD;
          -  Patients hospitalized for less than 48 hours before admission to intensive care&#xD;
             (selection of patients without malnutrition and immunosuppression acquired in&#xD;
             hospital) *;&#xD;
&#xD;
          -  Patients under invasive mechanical ventilation with a foreseeable ventilation&#xD;
             duration&gt; 2 days **;&#xD;
&#xD;
          -  Exclusive enteral nutrition;&#xD;
&#xD;
          -  Affiliation to a social security scheme;&#xD;
&#xD;
          -  Consent signed by the patient, relative or legal representative or inclusion under&#xD;
             emergency procedure&#xD;
&#xD;
        Non Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancy in progress;&#xD;
&#xD;
          -  Morbid obesity (BMI&gt; 40);&#xD;
&#xD;
          -  State of immunosuppression defined by at least one of these criteria: continuous&#xD;
             administration of steroids at any dose for more than one month before hospitalization,&#xD;
             steroids at high doses (&gt; 0.5 mg / kg / day of methylprednisolone or equivalent),&#xD;
             radiotherapy or chemotherapy in the previous year, proven humoral or cellular&#xD;
             deficiency;&#xD;
&#xD;
          -  Contraindication to enteral nutrition (SRLF 2016 recommendations: &quot;Enteral nutrition&#xD;
             should probably not be used upstream of a high flow digestive fistula in cases of&#xD;
             intestinal obstruction, ischemia of the small intestine or digestive hemorrhage.&#xD;
             active (Strong agreement) &quot;);&#xD;
&#xD;
          -  Participation in intervention research on a drug, or intervention research that could&#xD;
             impact the immune system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Institution of immunosuppressive therapy such as chemotherapy, cyclophosphamide, high&#xD;
        dose corticosteroid therapy (&gt; 0.5 mg / kg / day).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mathieu Lesouhaitier, MD</last_name>
    <phone>0033299284321</phone>
    <email>mathieu.lesouhaitier@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Marc TadiÃ©, MD</last_name>
    <phone>0033299284321</phone>
    <email>jean-marc.tadie@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rennes University Hospital - Medical ICU</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mathieu Lesouhaitier, MD</last_name>
      <email>mathieu.lesouhaitier@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Mathieu Lesouhaitier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital - Surgical ICU</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Yoann Launey, MD</last_name>
      <email>yoann.launey@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Yoann Launey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BesanÃ§on University Hospital</name>
      <address>
        <city>BesanÃ§on</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>GaÃ«l Piton, MD</last_name>
      <email>gpiton@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>GaÃ«l Piton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Mans Hospital</name>
      <address>
        <city>Le Mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Christophe Guitton, MD</last_name>
      <email>cguitton@ch-lemans.fr</email>
    </contact>
    <investigator>
      <last_name>gpiton@chu-besancon.fr Guitton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Charlotte Salmon-GandonniÃ¨re, MD</last_name>
      <email>charlotte.salmon@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte Salmon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

